
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HG-CT-1
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Hemogenyx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Made Scientific and Hemogenyx Announce Technology Transfer and Manufacturing Partnership
Details : The partnership aims to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 08, 2025
Lead Product(s) : HG-CT-1
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Hemogenyx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SENT-001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Sentinel BioTherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Made Scientific and Sentinel Announce Partnership to Advance ePP Encapsulated Cell Therapy
Details : Made Scientific is partnering with Sentinel BioTherapeutics to manufacture SENT-001, an allogeneic encapsulated cell therapy delivering IL-2 for solid tumor immunotherapy.
Product Name : SENT-001
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : SENT-001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Sentinel BioTherapeutics
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TVGN-489
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Tevogen Bio
Deal Size : Undisclosed
Deal Type : Partnership
Details : Experts from both entities will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
March 15, 2021
Lead Product(s) : TVGN-489
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Tevogen Bio
Deal Size : Undisclosed
Deal Type : Partnership
